HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

dasatinib (BMS 354825)

antineoplastic; an ABL kinase inhibitor that counters resistance to imatinib; structure in first source

Also Known As:

BMS 354825; (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; BMS-354825; BMS354825; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; Sprycel

Networked: 966 relevant articles (124 outcomes, 183 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Cortes, Jorge: 34 articles (04/2015 - 06/2006)
2.	Kantarjian, Hagop: 31 articles (11/2015 - 06/2006)
3.	Hochhaus, Andreas: 29 articles (04/2014 - 03/2007)
4.	Jabbour, Elias: 20 articles (12/2015 - 11/2006)
5.	O'Brien, Susan: 20 articles (11/2015 - 06/2006)
6.	Lee, Francis Y: 18 articles (02/2012 - 03/2005)
7.	Kantarjian, Hagop M: 17 articles (12/2015 - 02/2007)
8.	Cortes, Jorge E: 17 articles (12/2015 - 05/2008)
9.	Shah, Neil P: 17 articles (11/2015 - 03/2005)
10.	Breccia, Massimo: 16 articles (06/2013 - 01/2007)

Related Diseases

1.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/01/2012 - "Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia." 11/01/2011 - "Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features." 11/01/2010 - "We experienced a case of chronic myelogenous leukemia (CML) treated successfully with low-dose dasatinib (20 mg/day). " 01/01/2014 - "Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia." 03/01/2012 - "Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation."
2.	Philadelphia Chromosome 03/01/2013 - "MLN0128 also boosted the efficacy of dasatinib (DA) in Philadelphia Chromosome-positive (Ph+) specimens. " 09/10/2011 - "Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia." 05/01/2007 - "Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias." 06/01/2010 - "Achievement of complete donor-type chimerism and remission with dasatinib in Philadelphia chromosome-positive ALL relapsing after allogeneic transplantation." 11/01/2015 - "Cost-Effectiveness of Ponatinib Followed By Stem Cell Transplant Versus Best Supportive Care For Uk Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia After Failure of Dasatinib."
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/01/2012 - "Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification." 03/01/2009 - "Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia." 09/01/2012 - "In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia." 08/01/2012 - "H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia." 01/01/2012 - "Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation."
4.	Neoplasms (Cancer) 03/01/2010 - "The clinical efficacy of dasatinib in a wide variety of solid tumors and important Phase I/II studies utilizing dasatinib and the optimal dosage used in solid tumors. " 11/01/2013 - "A significant reduction (P < 0.001) in tumor cell migration and invasion was also found following dasatinib treatment alone or in combination. " 04/01/2009 - "In contrast, tumor FDG uptake showed no significant reduction with dasatinib therapy (8.13+/-0.45% ID/g in treated versus 10.39+/-1.04% ID/g in controls; P=0.170). " 01/01/2015 - "Although the combined use of Src inhibitor Dasatinib with other chemotherapeutic agents has shown superior efficacy for cancer treatment, the mechanisms that lead to enhanced sensitivity of Dasatinib are not completely understood. " 01/01/2006 - "Our studies suggest that dasatinib may have clinical efficacy against human neoplasms that are associated with gain-of-function KIT mutations."
5.	Leukemia 01/01/2014 - "Furthermore, two recent studies showed dasatinib to be effective in inhibiting the in vitro growth of cells from leukemia patients with c-Cbl RING finger and linker domain mutations. " 01/01/2014 - "Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI-resistant phenotype of human Ph+ ALL. " 07/01/2013 - "Dasatinib 60 mg/m(2) and 80 mg/m(2) once-daily dosing were selected for phase II studies in children with Ph-positive leukemias." 11/01/2012 - "In this article, we review preclinical and clinical studies with dasatinib for the therapy of Philadelphia (Ph)-positive leukemias. " 11/01/2015 - "Symptoms of PAH in dasatinib-treated leukemia patients should prompt a thorough workup, including consideration of confirmatory right-heart catheterization. "

Related Drugs and Biologics

1.	imatinib (Gleevec)
2.	4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
3.	Protein-Tyrosine Kinases (Tyrosine Kinase)
4.	dasatinib (BMS 354825)
5.	Phosphotransferases (Kinase)
6.	src-Family Kinases
7.	Epidermal Growth Factor Receptor (EGF Receptor)
8.	bortezomib (Velcade)
9.	Adenosine Triphosphate (ATP)
10.	docetaxel (Taxotere)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Castration
4.	Stem Cell Transplantation
5.	Transplantation (Transplant Recipients)